Clinical Research

Clinical research at the OVID Clinic Berlin

We want to continuously improve the care of our patients. This is why we conduct research on psychotherapeutic and psychopharmacological topics in the outpatient area of the OVID Clinic Berlin. They are intended to contribute to the development and evaluation of innovative approaches. 
This includes researching the effectiveness and the process of continuing training in augmented psychotherapy for doctors and psychotherapists and evaluating the treatment concept of the OVID Clinic Berlin itself. We are also a study center for research projects in the field of the use of psychedelic substances for the treatment of mental disorders.

Study on the efficacy of 5-MeO-DMT in the treatment of treatment-resistant depression 

Since April 2024, we have been participating as a study center in a clinical trial for the treatment of treatment-resistant depression with the psychedelic compound BPL-003 (5-MeO-DMT).

What is the study about?

The aim of the study is to investigate whether and at what dosage the compound BPL-003 (intranasal 5-MeO-DMT) in combination with psychological support can help patients suffering from treatment-resistant depression who have not yet had a positive course of treatment.

The aim is to investigate the safety and effectiveness of a single administration of the active substance in a placebo-controlled study. 

When does the study start? And what are the costs for participants?

Participation in the study is free of charge for patients and enrollment is possible immediately.

Who is organizing the study?

This is a Phase IIb Approval Study by Beckley Psytech (UK), in which 40 study centers worldwide are participating.

Inclusion criteria for the study

People between the ages of 18 and 75 who fulfill the following requirements are eligible to participate:

  • You suffer from at least moderate major depression and the depression is demonstrably resistant to treatment. This means that you have had at least two (but no more than five) unsuccessful treatments with different antidepressants during the current episode of illness
  • You are able to discontinue your psychiatric medication under medical supervision if necessary

Exclusion criteria

The following criteria prevent participation in the study:

  • The presence of a serious physical or neurological illness
  • A personality disorder, schizophrenia or other psychotic disorder as well as the comorbid presence of another severe psychiatric disorder
  • Women of childbearing age who are not willing to use safe contraception during participation in the study
  • You are pregnant or currently breastfeeding
  • You regularly take psychotropic substances

The study schedule

225 participants from 6 countries will be able to take part in the study at 40 study centers. Study participation lasts up to 16 weeks in total and comprises several phases with a total of 11 appointments, of which at least 9 must take place on site:

  • A screening period of max. six weeks duration
  • Psychological preparation sessions (approx. two weeks)
  • One substance session and integration sessions (approx. two weeks)
  • Follow-up discussions and visits (approx. six weeks)

During participation in the study, some of the test subjects receive the active substance, while others receive a placebo. If they have received a placebo, under certain circumstances they can take part in an open extended part of the study (approx. nine weeks), which includes a further session using the active substance.

Would you like to take part or do you have any questions?

Thank you for your interest. Please send us a message to 

Further information on the sponsor of the study can be found on the Beckley Psytech website or more generally at